Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Roadmap On Improvements To EMA's Literature Monitoring Service Due By Year End

Executive Summary

The European Medicines Agency will be looking for quick wins as well as long-term improvements when it revises its medical literature monitoring service. It will soon publish a roadmap for improving the service with details of when the changes might occur.

You may also be interested in...



Roadmap To Improve EMA’s Medical Literature Monitoring Service Due Soon

A roadmap to improve the European Medicines Agency’s medical literature monitoring service will be published soon. While some of industry’s suggestions to expand or improve the service have been rejected, many others have either already been implemented or will materialize in the near future.

EU Generic Industry Group Looks At Radical Options To Simplify Pharmacovigilance Tasks

From looking at ways to reduce the number of audits undertaken by companies to fulfil their pharmacovigilance obligations to calling for harmonized assessment of risk management plans, the EU generics and biosimilars industry group Medicines for Europe says it is ready to explore some radical proposals to simplify the current pharmacovigilance requirements.

EMA Tackles Complexities Introduced By Literature Monitoring Service

The European Medicines Agency is looking at ways to improve and simplify its medical literature monitoring service, which has created new complexities for the generics pharmaceutical industry.

Related Content

Topics

UsernamePublicRestriction

Register

LL1134044

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel